Patent ID: 8492328
Filing Date: 2013-07-23
Classification: C12Q

Abstract:
1. A method for predicting the likelihood a patient will respond therapeutically to a method of treating cancer comprising administering an IGF1R inhibitor, said method comprises: (a) measuring the expression level of the IGFBP6 biomarker in a biological cancer sample of said patient; (b) determining whether said sample has an increased level of said biomarker in said cancer sample that is at least 2-fold higher relative to a predetermined level of said biomarker, (c) classifying said patient as having an increased likelihood of responding therapeutically to said method of treating cancer if said patient has a decreased level of said biomarker, and (d) administering (2S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N-(6-fluoro-3-pyridinyl)-2-methyl-2-pyrrolidinecarboxamide to said patient.